Biogen to buy Texas-based rare disease co. Reata Pharmaceuticals for $7.2B
Biogen is paying $7.2 billion to buy a DFW biotech as the new CEO makes good on his promise to expand into the rare disease space. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 28, 2023 Category: Biotechnology Authors: Rowan Walrath Source Type: news
Biogen to buy a Texas-based rare disease firm for $7.2B
Biogen is paying $7.2 billion to buy a Texas-based biotech as new CEO makes good on his promise to expand into the rare disease space. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 28, 2023 Category: Biotechnology Authors: Rowan Walrath Source Type: news
Biogen Looks To Bulk Up Rare Disease Portfolio With $7.3 Billion Acquisition
Biogen will buy Reata Pharmaceuticals and its Friedreich's ataxia drug in a $7.3 billion deal. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 28, 2023 Category: Pharmaceuticals Authors: Mary Whitfill Roeloffs, Forbes Staff Tags: Business /business Innovation /innovation Healthcare /healthcare Breaking breaking-news topline Source Type: news
Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio
Biogen said it would buy biotech firm Reata Pharmaceuticals for roughly $6.5 billion to expand its presence in the rare disease drugs market. Through the deal, Biogen will gain Plano, Texas-based Reata's recently approved drug Skyclarys to treat a rare genetic disorder that causes progressive…#biogen #reatapharmaceuticals #plano #reata #leqembi (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2023 Category: Consumer Health News Source Type: news
Biogen to Buy Reata for $7.3 Billion in Rare-Disease Expansion
(Source: Reuters: Health)
Source: Reuters: Health - July 28, 2023 Category: Consumer Health News Source Type: news
Biogen to bulk up rare disease treatments with $7 billion Reata acquisition
Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments. The Alzheimer’s treatment developer said Friday it will pay $172.50 in cash for each share of Reata in a deal it expects to close by the end of this year. Plano, Texas-based Reata focuses…#biogen #reatapharmaceuticals #reata #plano #fda #freidreich #techfidera #tysabri #spinraza #leqembi (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2023 Category: Consumer Health News Source Type: news
Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio
said it would buy biotech firm Reata Pharmaceuticals (RETA.O) for roughly $6.5 billion to expand its presence in the rare disease drugs market. Biogen will pay $172.50 per share in cash, which represents a 58.9% premium to Reata's last closing price. It expects to finance the acquisition with cash…#biogen #reatapharmaceuticals #reata #bhanvisatija #bengaluru (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2023 Category: Consumer Health News Source Type: news
Invitation to Roche ’s Pharma Day 2023
The Roche Investor Relations team would like to invite you to the Roche Pharma Day that will take place in London on Monday, 11 September 2023, starting at 10:00 BST and will finish at 14:30 BST with a reception.The Roche Pharma Day will address the following topics: Group / Pharma strategyCommercial growth driversPipeline updatesOncology, Hematology, Neuroscience, Ophthalmology, Immunology Presenters include:ThomasSchinecker, CEO Roche GroupTeresa Graham, CEO Roche PharmaceuticalsLevi Garraway, Chief Medical Officer and Head of Global Product DevelopmentCharlie Fuchs, Senior Vice President and Global Head of Oncol...
Source: Roche Investor Update - July 21, 2023 Category: Pharmaceuticals Source Type: news
GST exemption on medicines for rare diseases is unlikely to provide any relief to those in need: Health activists
The recent GST exemption on medicines for rare diseases in India is unlikely to help many patients as the drugs are still too expensive, say health activists. Activists say they had hoped for a tax exemption for medicines already approved by India's drug regulator and available locally. With patient requests for exemption for Indian medicines, the Supreme Court acknowledged that the health ministry must decide but Indian GST exemption on medicines remains pending. (Source: The Economic Times)
Source: The Economic Times - July 13, 2023 Category: Consumer Health News Source Type: news
BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer
Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases
NEW YORK, July 12, 2023 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (N... Regenerative Medicine, Personnel BrainStorm Cell Therapeutics, NurOwn, stem cell (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 12, 2023 Category: Pharmaceuticals Source Type: news
Whole Genome Sequencing Boosts Diagnosis of Rare Disease in Infants
(MedPage Today) -- Whole genome sequencing captured almost twice as many genetic abnormalities that may be responsible for disease in infants, compared with a standard targeted test, researchers found.
In the Genomic Medicine for Ill Neonates... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 12, 2023 Category: American Health Source Type: news
Different US/UK Initiatives Each Plan to Sequence the Genomes of 100,000 Newborns to Identify Treatable Rare Diseases Undetectable to Standard Screening Tests
Both programs seek to achieve early diagnosis by detecting a range of disorders where an existing treatment can be given as early as possible Two separate genetic sequencing projects—one in the United Kingdom and one in New York City—aim to perform whole-genome sequencing for clinical laboratory diagnostic purposes on 100,000 newborns each to identify up […]
The post Different US/UK Initiatives Each Plan to Sequence the Genomes of 100,000 Newborns to Identify Treatable Rare Diseases Undetectable to Standard Screening Tests appeared first on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - July 10, 2023 Category: Laboratory Medicine Authors: swallask Tags: Laboratory Pathology Laboratory Resources Laboratory Testing Molecular Diagnostics, Genetic Testing, Whole Gene Sequencing Precision Medicine Source Type: news
Controversial Gene-Editing Scientist Proposes New Experiment to Prevent Alzheimer ’s
The Chinese scientist who was at the center of global condemnation for altering babies’ genes wants to use a similar technique to prevent Alzheimer’s disease.
He Jiankui, who shocked the world in 2018 by announcing he had altered the genes of embryos to make them resistant to HIV, is now proposing to test whether a particular genetic mutation confers protection against the most common cause of dementia. No human embryos would be implanted to create a pregnancy in the study — meaning no babies will be born — and it will first be trialled on a mouse, according to a post on his Twitter account late las...
Source: TIME: Health - July 4, 2023 Category: Consumer Health News Authors: Bloomberg News Tags: Uncategorized China Genetics wire Source Type: news
Introduction to AAV Gene Therapies
Small-scale successes in rare disease treatments prime large-scale industry innovations. (Source: The Scientist)
Source: The Scientist - June 29, 2023 Category: Science Tags: Sponsored Article The Scientist University Source Type: news
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
Lobe Sciences Ltd. LOBEF, a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has commenced its Phase 1 clinical study on proprietary psilocin analog L-130. Conducted in Jordan under the country’s Food and Drug…#lobesciencesltd #phase1 #jordan #phase2 #cch #fda #phase2a #lobe #philipyoung #oliadanilevich (Source: Reuters: Health)
Source: Reuters: Health - June 28, 2023 Category: Consumer Health News Source Type: news
